GORE TAG Endoprosthesis for Aortic Aneurysm

Overseen By DeAnne Hart

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: W.L.Gore & Associates

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

A prospective multi-center post-market study collecting outcomes through at least 5-years and up to 10-years post procedure for subjects treated with the TBE Device in Zone 0/1 as part of routine clinical practice.

Are You a Good Fit for This Trial?

Inclusion Criteria

Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements

Patient has been or is intended to be treated with the TBE Device in Zone 0 or Zone 1

I am 18 years old or older.

Exclusion Criteria

Patient who is, at the time of consent, unlikely to be available for defined follow-up visits

Patient with exclusion criteria required by local law

Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or investigational device study within 12 months of study enrollment. Subjects cannot be enrolled in another Gore study.

What Are the Treatments Tested in This Trial?

Interventions

• GORE® TAG® Thoracic Branch Endoprosthesis

How Is the Trial Designed?

Group I: GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

W.L.Gore & Associates

Lead Sponsor

Trials

103

Recruited

32,900+

Bret Snyder

W.L.Gore & Associates

Chief Executive Officer since 2020

MBA from Stanford University

Dr. John Doe

W.L.Gore & Associates

Chief Medical Officer since 2023

MD from Harvard Medical School